Table 5 |
||||||
|
Prognostic factors. Cox regression analysis for patients' survival. |
||||||
|
Univariate |
Multivariate |
|||||
|
|
||||||
|
HR |
95% CI |
P |
HR |
95% CI |
P |
|
|
|
||||||
|
Age |
||||||
|
< = 65 |
1 |
- |
- |
|||
|
> 65 |
0.83 |
0.57-1.21 |
0.329 |
|||
|
Performance status |
||||||
|
0 |
1 |
- |
- |
1 |
- |
- |
|
1-2 |
1.96 |
1.32-2.90 |
0.001 |
1.89 |
1.25-2.88 |
0.003 |
|
Previous exposure to taxanes |
||||||
|
No |
1 |
- |
- |
|||
|
Yes |
1.18 |
0.62-2.27 |
0.610 |
|||
|
Disease status |
||||||
|
Non-measurable |
1 |
- |
- |
|||
|
Measurable |
1.49 |
0.88-2.55 |
0.141 |
|||
|
Platinum-free interval |
||||||
|
6-12 months |
1 |
- |
- |
1 |
- |
- |
|
12.1-24 months |
0.58 |
0.37-0.89 |
0.013 |
0.54 |
0.34-0.86 |
0.009 |
|
> 24 months |
0.37 |
0.22-0.61 |
< 0.001 |
0.36 |
0.21-0.61 |
< 0.001 |
|
Randomization group |
||||||
|
A |
1 |
- |
- |
1 |
- |
- |
|
B |
1.15 |
0.78-1.66 |
0.455 |
1.19 |
0.80-1.76 |
0.399 |
|
|
||||||
|
CI, confidence interval; HR, (Hazard Ratio) |
||||||
|
Bafaloukos et al. BMC Medicine 2010 8:3 doi:10.1186/1741-7015-8-3 |
||||||
